CBM Cambrex Corporation

Cambrex to Present at Upcoming Investor Conferences in September

Cambrex to Present at Upcoming Investor Conferences in September

EAST RUTHERFORD, N.J., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that company management will present at the following investor conferences in September:

2018 Wells Fargo Healthcare Conference

Date:  Wednesday, September 5, 2018

Time:  3:00 p.m. EDT

Location:  Boston, MA

Morgan Stanley 16th Annual Global Healthcare Conference

Date:  Friday, September 14, 2018

Time:  9:55 a.m. EDT

Location:  New York, NY

The live audio webcast and slide presentations can be accessed from the Cambrex website at in the Investors section under “Webcasts & Presentations”, and replays will be available for 90 days after the live events conclude.

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing.  For more information, please visit .

Contact:         Stephanie LaFiura
 IR Associate
 Tel:
 Email:

EN
29/08/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cambrex Corporation

Moody's Ratings downgrades Cambrex's CFR to B3, outlook remains negati...

Moody's Ratings (Moody's) downgraded the ratings of Cambrex Corporation's ("Cambrex") including the Corporate Family Rating (CFR) to B3 from B2 and the Probability of Default Rating (PDR) to B3-PD from B2-PD. Concurrently, Moody's downgraded the rating of the backed senior secured first lien bank fa...

Cambrex Corporation: Update to credit analysis following change of out...

Our credit view of this issuer reflects its high financial leverage and aggressive M&A posture offset by its high quality manufacturing facilities, and one of only a few CDMO’s of scale.

Moody's changes Cambrex's outlook to negative; affirms B2 CFR

Moody's Investors Service ("Moody's") today affirmed Cambrex Corporation's ("Cambrex") B2 corporate family rating (CFR) and B2-PD probability of default rating (PDR). Concurrently, Moody's affirmed the B2 rating of the backed senior secured first lien bank facility. The outlook was changed to negati...

Cambrex Corporation: Update to credit analysis

Cambrex' credit profile reflects its high financial leverage and concentration in small molecules offset by its capabilities as a fully integrated CDMO and strong demand for its services.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch